Recent research has demonstrated that patients with hypercholesterolemia have elevated fibroblast growth factor 19 (FGF19), which is positively correlated with pro-atherogenic ceramide levels [123]. This evidence concerns the gene FGF19 and familial hypercholesterolemia.